Review journal of neurological & medical sciences review.
June 10, 2026
Sidra Shehzad, Neelam Ehsan, Fatima Fayyaz et al.
Cannabis-induced psychosis is a serious psychiatric condition and is associated with chronic and prolonged cannabis use. The chronic use of cannabis often results in significant cognitive, behavioural and psychosocial impairment. The present case study examined the case history of SM. He was a 45-year-old married male with a twenty-year history of cannabis dependence. He was presented with...
Frontiers in Psychiatry
June 10, 2026
Justyna Śniadach, Sylwia Szymkowiak, Przemysław Osip et al.
Background: Cannabis use has increased across Europe over the last decade, accompanied by growing availability of high-potency THC products and rising psychiatric presentations. Despite these trends, European countries differ substantially in monitoring systems, clinical preparedness and public health responses. These disparities are especially visible between Western Europe, which has more...
International Journal of Clinical Pharmacy
June 9, 2026
Leah Roberts, Craig Cumming, C. Budgeon et al.
Anxiety disorders are among the most prevalent and disabling mental health conditions and are associated with impairments in quality of life (QoL). Previous studies have examined medicinal cannabis for anxiety and QoL using short-term follow-up or cross-sectional surveys. However, there is little longitudinal qualitative research examining how patients experience QoL changes. To explore the...
Debates em Psiquiatria
June 9, 2026
L. Baldaçara, G. A. Rocha, Roberto Mendes Dos Santos et al.
Introduction: Cannabis use and the availability of high-potency cannabis-derived products and synthetic cannabinoids have increased worldwide, contributing to a growing burden of emergency presentations involving intoxication, agitation, psychosis, cardiovascular complications, and other acute toxic effects. Objective: This review aimed to update the clinical approach to emergencies related to...
Clinical Integration and Specialty Practice in Cannabis Nursing
June 5, 2026
Kathleen Marie Pinto Araya
Cannabis use is increasing across the United States, creating clinical, ethical, and educational challenges for Psychiatric-Mental Health Nurse Practitioners (PMHNPs). The evolving legal landscape, including the 2025 federal directive to reclassify cannabis from Schedule I to Schedule III, expands research opportunities while maintaining regulatory complexity. Evidence shows cannabidiol (CBD)...
American Journal of Psychiatry
June 3, 2026
Deepak C D'Souza, Jose A Cortes-Briones, Justin Raj et al.
OBJECTIVE Cannabis use is a known risk factor for psychosis, but it remains unclear whether cannabis-associated psychosis (CAP) differs meaningfully from non-cannabis-associated psychosis (NCAP) in clinical presentation, biology, or illness course. The objective of this study was to characterize the presentation and course of first-episode psychosis with and without cannabis exposure. METHODS...
Neuroscience & Biobehavioral Reviews
June 3, 2026
Isabella Goodwin, Dominic Oliver, Edward Chesney et al.
Global shifts towards the liberalisation of cannabis policies have increased the potency of cannabis products, alongside their accessibility, diversity, and the number of inexperienced cannabis consumers. There is a lack of systematic evidence on the subjective effects of cannabis' main psychoactive compound, Δ9-tetrahydrocannabinol (THC). We systematically reviewed and meta-analysed data from...
Journal of Addiction Medicine
June 3, 2026
Ynhi T Thomas, Mubeen Iqbal, Chung J Mun et al.
Kratom ( Mitragyna speciosa ) is a psychoactive botanical with a long history of use in Southeast Asia and growing uptake in the United States for its analgesic, stimulant, and mood-altering properties. The evidence base remains limited, and retail products vary widely in composition and potency. This narrative review highlights what is known about kratom's pharmacology and suggests a practical...
Neuropsychopharmacology
June 2, 2026
Sarah A Thomas, Meghan A Gonsalves, Gillian LeBlanc et al.
Approximately 10-20% of U.S. adolescents report past-year cannabis use (CU). Although regular CU beginning in adolescence is expected to blunt dopamine-related neurophysiology, this hypothesis has not been tested in adolescents due to methodological limitations. However, neurophysiology contributing to dopamine can be noninvasively indexed via subcortical tissue iron measured with magnetic...
The American Journal of Medicine
June 2026
Annie Massart, TaRessa Wills, Malavika Kapuria et al.
Cannabis products are widely accessible, yet adult presentations after unintentional ingestion of psychoactive Δ9-tetrahydrocannabinol (THC), synthetic cannabinoids, or adulterated cannabidiol (CBD) remain poorly described. This scoping review summarizes adult unintentional THC exposures among adults seeking medical care with confirmed ingestion, verified either by positive THC urine drug...